Bavencio by Merck passed the Cancer Drugs Benefit Committee

as an indication for urinary tract epithelial cell cancer treatment

In the case of Brukinsa, only WM, and in the case of Lynparza, only BRCA mutated prostate cancer were se

Bavencio by Merck

Immuno-cancer drug Merck Bavencio passed the Cancer Drugs Benefit Appraisal Committee as an indication for urinary tract epithelial cell cancer.

 

The HIRA's Cancer Drugs Benefit Appraisal Committee held the 4th meeting in 2022 on the 6th and announced that Bavencio's standards for urinary epithelial cell cancer have been set.

 

Cancer Drugs Benefit Appraisal Committee also set standards only for WM in the case of BeiGene's Brukinsa, which applied for benefits on the same day.

 

It is expected to be used as a monotherapy in adult WM patients who have previously received more than one treatment.

 

However, Brukinsa failed to set the standard for "single therapy in adult patients with osmotic cell lymphoma (MCL) who have previously received more than one treatment." Lynparza of AstraZeneca, Korea, known as an ovarian cancer treatment, also started to expand the standard, but it was bittersweet.

 

The standards were set for the treatment of adult patients with BRCA mutagenic castration resistant prostate cancer, who had previously experienced disease progression after treatment with new hormone treatments, but the remaining three indications were not set.

 

Combination maintenance therapy in adult patients with highly epithelial ovarian cancer, ovarian cancer, or primary peritoneal cancer, which is HRD-positive (defined as BRCA mutation or dielectric instability) in response to primary platinum-based chemotherapy and Bevacizumab combination therapy, did not pass the Cancer Drugs Benefit Application Committee.

 

The treatment of gBRCA mutant HER2-negative metastatic breast cancer adult patients with previous chemotherapy experience and maintenance therapy of gBRCA mutant metastatic pancreatic cancer adult patients who did not undergo primary platinum-based chemotherapy for at least 16 weeks were not recognized.